Turn Therapeutics Inc. - Common Stock (NQ:TTRX)

13.33 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Turn Therapeutics Inc. - Common Stock

< Previous 1 2 Next >

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

September 10, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer

September 09, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

August 20, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

August 12, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

July 28, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout ↗

July 11, 2026

Turn Therapeutics (NASDAQ:TTRX) outlined the final stage two design and data-driven expansion of its GX-03 phase II program in atopic dermatitis during an investor update call, saying the revised...

Via MarketBeat

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

July 07, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

July 06, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

June 01, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

May 27, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

May 19, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

May 18, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 11, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

March 31, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group

March 24, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs

February 17, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences

February 09, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

January 07, 2026

Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and Expansion

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 13, 2025

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.

November 11, 2025

Conversation Centered Around Healthcare Communications and Pandemic Preparedness

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine

November 11, 2025

Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications

November 04, 2025

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline

October 30, 2025

Agreement combines Turn’s PermaFusion® delivery platform with Medline’s global scale and distribution capabilities to advance professional and retail product opportunities

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones

October 22, 2025

Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025

October 20, 2025

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors

October 15, 2025

Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Appoints Arthur Golden to Board of Directors

October 14, 2025

Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs

From Turn Therapeutics

Via GlobeNewswire

Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings ↗

October 09, 2025

Via Benzinga

Topics Stocks

US Stocks Mixed; Nasdaq Falls Over 50 Points ↗

October 09, 2025

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.